Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer

Recruiting now

Conditions studied: Ovarian Cancer

In brief

Ovarian cancer is a highly lethal gynecological malignancy, often diagnosed at an advanced stage, with high rates of recurrence within 1-2 years after frontline treatment. Current guidelines recommend monitoring tumor markers CA125 and HE4 for disease progression, but these markers may not detect recurrence or disease progression when their levels are below the detection limit. Therefore, there is a need to identify new prognostic biomarkers and monitor their dynamic changes for effective risk stratification and personalized treatment in patients with ovarian cancer

Key facts

Study ID

NCT06019923

Run by

Women's Hospital School Of Medicine Zhejiang University

People needed

100

Starts

2023-10-26

Expected to finish

2027-09-10

Last updated by the study team

2025-07-17

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age between 18 and 75 years;
• Pathological diagnosis of high-grade serous ovarian cancer;
• Newly diagnosed ovarian cancer case without prior neoadjuvant therapy.

You may not qualify if…

• Non-primary (recurrent) patients;
• Ovarian cancer patients who have not undergone surgical treatment;
• Patients with a history of other malignancies.

Where it is running

• Women's Hospital School of Medicine Zhejiang University — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.